Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasm Female × palbociclib × Breast × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 170 Neoplasm Metastasis 18 Ovarian Neoplasms 7 Neoplasms 7 Breast Diseases 6 Triple Negative Breast Neoplasms 3 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Neoplasms by Site 3 Head and Neck Neoplasms 3 Endometrial Neoplasms 3 Advanced Breast Cancer 3 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma 2 Recurrence 2 Neoplasm, Residual 2 Lung Neoplasms 2 Inflammation 2 Hereditary Sensory and Autonomic Neuropathies 2 Fallopian Tube Neoplasms 2 Estrogen Receptor-positive Breast Cancer 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Cardiovascular Diseases 2 Carcinoma, Ovarian Epithelial 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms, Male 2 Brain Neoplasms 2 Venous Thromboembolism 1 Uterine Cervical Neoplasms 1

Interventions

Fulvestrant 2 venetoclax 1 pyrotinib 1 pertuzumab 1 penpulimab 1 palbociclib 1 dalpiciclib 1 anlotinib 1 Tretinoin 1 Trastuzumab 1 Ropivacaine 1 Radiosurgery 1 Propofol 1 Patient Reported Outcome Measures 1 Paclitaxel 1 Ondansetron 1 Morphine 1 Letrozole 1 Induction Chemotherapy 1 Etoricoxib 1 Docetaxel 1 Diagnostic Imaging 1 Carboplatin 1 Capecitabine 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03900884 2024-11-07

PALVEN

Peter MacCallum Cancer Centre, Australia

Phase 1 Active not recruiting

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon ⚡